01/06/2026
Happy New Year to all, and I hope that everyone is enjoying time with loved ones. Meanwhile, we have very exciting results from our randomized controlled trial, and these have just been posted as a preprint: https://www.preprints.org/frontend/manuscript/8118568f183e2ba91ec2a1d3b3d08fb9/download_pub . These results will be submitted for peer review in February; here is a summary of some of the key findings:
(1) Our protocol produced statistically significant improvements in memory, executive function, brain processing speed, and overall cognition, whereas the standard of care treatment did not;
(2) cognitive symptoms were markedly improved by our protocol, as noted both by the patients and their partners;
(3) statistically significant improvements in multiple health parameters occurred with our protocol: better blood pressure, body mass index, insulin sensitivity, hemoglobin A1c, lipid profiles (“cholesterol”), and methylation.
(4) The overall effect of our protocol was greater than any other treatment for cognitive decline—and 600% better (i.e., 7 times) the effect of Leqembi, the Alzheimer’s drug (you can see this in Figure 10 in the preprint).
Here’s to continued great progress in 2026—let’s all work together to reduce the global burden of dementia. We can do it.
